The good (logMAR), the bad (Snellen) and the ugly (BCVA, number of letters read) of visual acuity measurement

Elliott, David B.

doi:10.1111/opo.12310

Cited by 76 publications

(76 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comorbidities, difficulty scheduling appointments, and a negative therapeutic experience are just a few examples of real-world factors that may result in actual clinical outcomes being different from those found in a controlled clinical setting. The 5.58-letter increase in VA at 12 months of ranibizumab therapy is consistent with prior meta-analyses 50,51 but lower than what was reported in landmark clinical trials. 4,13,18,52 However, the landmark trials, such as VIEW I, VIEW II, ANCHOR, MARINA, and CATT, 4,13,18,52 all followed regular posologies, which were defined as regularly scheduled appointment regimens for ranibizumab injections as opposed to being treated on an asneeded basis.…”

Section: Discussionsupporting

confidence: 86%

One‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

One‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The multi‐faceted nature of measurable visual outcomes has resulted in differences in the reporting of published results. For example, the unit of measurement for best corrected VA may be reported in standardized Early Treatment of Diabetic Retinopathy Study (EDTRS) letters read, the minimum angle of resolution (logMAR units), or in Snellen fractions (Elliott ). Changes in anatomical outcomes such as macular or foveal thickness, measured by optical coherence tomography (OCT), and neovascular lesion size or area have also been used to indicate effectiveness of AMD treatments.…”

Section: Introductionmentioning

confidence: 99%

One year effectiveness study of intravitreal aflibercept in neovascular age‐related macular degeneration: a meta‐analysis

Guo

Cheng

Etminan

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

The current body of evidence on the efficacy and safety of aflibercept for age-related macular degeneration (AMD) is steadily growing as large clinical trials and observational studies are continually completed. Our aim was to analyse 1-year visual acuity (VA) outcomes in response to aflibercept therapy and identify factors affecting treatment response using evidence generated from a pooled analysis of current studies. A literature review of multiple electronic databases (EMBASE, MEDLINE, MedMEME) revealed 12 studies meeting inclusion and exclusion criteria for statistical analysis. Treatment posology, baseline patient characteristics, study type, sample size and 12-month change in VA were pooled in a meta-analysis with VA change as the main outcome. Data were then stratified by study design and posology in subgroup analyses. A meta-regression was conducted to regress 12-month VA change against posology, baseline VA and age. Users of aflibercept experienced an overall increase of 7.37 letters (95% confidence interval: 6.27-8.48, p heterogeneity: <0.001) in VA at 12 months of follow-up. In subgroup analyses, mean VA change was higher for randomized control trials and cohorts following regular posology (>7 injections/year) compared to observational studies and irregular posology. The meta-regression showed larger VA gains with regular posology compared to an irregular posology, and decreased effect size as age increased. This meta-analysis strongly suggests improved VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. Increased injection frequency and younger age demonstrates a trend with improved outcomes.

show abstract

“…Visual acuity was converted to decimal notation to allow comparisons to be made between the different modalities of assessment used in the centers although this might not be a recommended approach [10]. Decimal notation was used to allow results from Snellen and logMAR charts to be combined.…”

Section: Visual Function Resultsmentioning

confidence: 99%

“…Study visit was coded in 3 ways, as a linear covariate, as a binary factor (baseline vs. each other visit), and as a full factor (5 levels, dummy coding with reference = baseline). Visual acuity was converted to decimal notation to allow comparisons to be made between the different modalities of assessment used in the centers [10]. Visual field characteristics were assessed either by means of static (mean deviation) or kinetic (visual field area -isopter III4e) strategies using different automated perimeters (Humphrey or Goldmann/Octopus respectively).…”

Section: Discussionmentioning

confidence: 99%

Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa: A Multicenter Safety Study of the OkuStim® System (TESOLA-Study)

Jolly

Wagner

Martus³

et al. 2019

Ophthalmic Res

View full text Add to dashboard Cite

Background: Transcorneal electrical stimulation (TES) has been suggested as a possible treatment for retinitis pigmentosa (RP). Objective: To expand the safety assessment of repeated applications of an electrical current from a DTL-like electrode in patients with RP. Methods: This single-arm open label interventional safety trial included a total of 105 RP patients from 11 European centers, who received weekly TES for 6 months on 1 eye followed by observation for another 6 months without stimulation. The primary outcome measure was safety, indicated by the frequency and severity of adverse events. Secondary measures included intraocular pres-J.K.J. and S.K.W. contributed equally to this work.TESOLA: Safety Study of the OkuStim ® System 235 sure and central retinal thickness. Visual field and visual acuity were examined using the methods available at each site. Results: Dry eye sensation was the most common adverse event recorded (37.5%). Serious adverse events secondary to TES were not observed. Most adverse events were mild and all resolved without sequelae. The secondary outcome measures revealed no significant or clinically relevant changes. Conclusion: The present results confirm the excellent safety profile of TES. Transient dry eye symptoms were the most common adverse event.

show abstract

The good (logMAR), the bad (Snellen) and the ugly (BCVA, number of letters read) of visual acuity measurement

Cited by 76 publications

References 33 publications

One‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis

One‐Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age‐Related Macular Degeneration: A Meta‐Analysis

One year effectiveness study of intravitreal aflibercept in neovascular age‐related macular degeneration: a meta‐analysis

Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa: A Multicenter Safety Study of the OkuStim® System (TESOLA-Study)

Contact Info

Product

Resources

About